Xtandi Archives -

News/ News/ News/ Oncology/ Sales and Marketing

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

Phil Taylor Bayer, Erleada, Nubeqa, Oncology, Orion, Prostate cancer, regulatory approval, Xtandi 0 Comment

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

https://pharmaphorum.com/news/bayer-bags-swift-ok-for-nubeqa-in-metastatic-prostate-cancer/

News/ News/ Sales and Marketing

Bayer triples sales forecast for prostate cancer drug Nubeqa

Phil Taylor Bayer, Erleada, Financial, Nubeqa, Prostate cancer, Xtandi 0 Comment

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up

Bayer triples sales forecast for prostate cancer drug Nubeqa

https://pharmaphorum.com/news/bayer-triples-sales-forecast-for-prostate-cancer-drug-nubeqa/

News/ News/ Oncology

Trial closes gap between Bayer’s Nubeqa and rivals in prostate cancer

Phil Taylor Astellas, Bayer, Erleada, Johnson & Johnson, Nubeqa, Oncology, Pfizer, Prostate cancer, Xtandi 0 Comment

Bayer’s Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track

Trial closes gap between Bayer’s Nubeqa and rivals in prostate cancer

https://pharmaphorum.com/news/trial-narrows-gap-between-bayers-nubeqa-and-rivals-in-prostate-cancer/

News/ News/ Oncology

Xtandi takes fight to prostate cancer rivals with survival data

Phil Taylor Astellas, Oncology, Pfizer, Prostate cancer, Xtandi 0 Comment

Pfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend

Xtandi takes fight to prostate cancer rivals with survival data

https://pharmaphorum.com/news/xtandi-takes-fight-to-prostate-cancer-rivals-with-survival-data/

News/ News/ Oncology

Xtandi catches up with Erleada in castration-sensitive prostate cancer

Phil Taylor Astellas, Erleada, Oncology, Pfizer, Prostate cancer, Xtandi 0 Comment

Pfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a

Xtandi catches up with Erleada in castration-sensitive prostate cancer

https://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/

News/ News/ Oncology

EMA starts review of Xtandi in hormone-sensitive prostate cancer

Phil Taylor Astellas, endocrinology, Johnson & Johnson, Oncology, Pfizer, Prostate cancer, Xtandi, Zytiga 0 Comment

The EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug

EMA starts review of Xtandi in hormone-sensitive prostate cancer

https://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/

News/ R&D

Prostate drug approved for use in non-metastatic cases

Joy Persaud FDA approval, Prostate cancer, Xtandi 0 Comment

The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic

Prostate drug approved for use in non-metastatic cases

https://pharmaphorum.com/news/prostate-drug-approved-for-use-in-non-metastatic-cases/

News/ US

Pfizer confirms $14bn Medivation merger

Richard Staines Medivation, Pfizer, Prostate cancer, Sanofi, Xtandi 0 Comment

Drug giant confirms press reports.

Pfizer confirms $14bn Medivation merger

https://pharmaphorum.com/news/pfizer-confirms-14bn-medivation-merger/

Trending

Xtandi

Login